Dodge & Cox Reduces $256M in Gilead Sciences, Inc. ($GILD)

Dodge & Cox trimmed its position in Gilead Sciences by over 2 million shares.

Written by Trueearnings · Published Jun 12, 2026, 10:05 AM EDT

Key Points

Dodge & Cox reduced its holdings in Gilead Sciences by 2,032,685 shares, a 7.7% decrease, now holding 24,250,826 shares.
Gilead Sciences trades at $125.87 with a market cap of $154.66 billion and a P/E ratio of 16.95.
The company offers a 2.61% dividend yield with a payout ratio of 43.4%.

Dodge & Cox has trimmed its stake in Gilead Sciences, Inc. (NasdaqGS: GILD), according to its latest 13F filing with the SEC. The fund reduced its holdings by 2,032,685 shares, a 7.7% decrease, leaving it with 24,250,826 shares valued at approximately $3.05 billion as of the end of the reporting period.

What Changed in Dodge & Cox's Gilead Sciences Position

Dodge & Cox reduced its investment in Gilead Sciences by over 2 million shares, bringing its total holdings down to 24.25 million shares. This reduction represents a 7.7% decrease from the previous 26.28 million shares. The move adjusted the fund's stake to a value of about $3.05 billion.

Gilead Sciences Stock Snapshot

Shares of Gilead Sciences traded near $125.87 recently. The company has a market capitalization of approximately $154.66 billion and a P/E ratio of 16.95. Its forward P/E is 12.99, reflecting expectations of future earnings growth. Gilead's stock has a 52-week low of $104.46 and a high of $157.29. The 50-day moving average is $133.26, while the 200-day moving average stands at $129.10. The company maintains a current ratio of 1.967 and a quick ratio of 1.536, with a debt-to-equity ratio of 94.635.

Recent Earnings

Gilead Sciences reported revenue of $29.74 billion, with a growth rate of 4.4%. The company's net margin stands at 30.993%, and it has a return on equity of 43.36%. Its earnings per share (EPS) is $7.35. The next earnings report is expected on May 7, 2026.

Dividend

Gilead Sciences offers an annual dividend rate of $3.28, yielding 2.61%. The dividend payout ratio is 43.4%, indicating a solid distribution relative to earnings.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company based in Foster City, California. It focuses on discovering, developing, and commercializing medicines for unmet medical needs. The company provides treatments for HIV, hepatitis, cancer, and other serious diseases. Led by CEO Daniel Patrick O'Day, Gilead employs around 17,000 people globally.

Bottom Line

Dodge & Cox's reduction of its Gilead Sciences position might indicate a rebalancing of its portfolio. Investors often track these filings to gauge institutional sentiment, but it's important to remember that 13F filings reflect past positions and may not represent current holdings.